argenx is trading at $860.54, up +4.23%, amid positive Phase 3 ALKIVIA data announced October 19.
- The autoimmune myositis trial met its primary endpoint, with a 15.4-point greater improvement versus placebo at Week 52.
- The company said the results will be presented at ACR Convergence.
- A market summary linked the announcement to a modest prior-session gain; available reporting does not separately confirm today’s intraday cause.